Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) FCF Margin (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed FCF Margin for 16 consecutive years, with 16.96% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 165.0% to 16.96% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 20.85% through Dec 2025, up 1052.0% year-over-year, with the annual reading at 20.85% for FY2025, 1052.0% up from the prior year.
  • FCF Margin hit 16.96% in Q4 2025 for Ani Pharmaceuticals, up from 16.66% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 178.3% in Q1 2021 to a low of 29.77% in Q1 2022.
  • Historically, FCF Margin has averaged 15.93% across 5 years, with a median of 15.03% in 2024.
  • Biggest five-year swings in FCF Margin: surged 17796bps in 2021 and later crashed -20807bps in 2022.
  • Year by year, FCF Margin stood at 20.58% in 2021, then soared by 76bps to 4.93% in 2022, then skyrocketed by 885bps to 38.74% in 2023, then crashed by -60bps to 15.31% in 2024, then rose by 11bps to 16.96% in 2025.
  • Business Quant data shows FCF Margin for ANIP at 16.96% in Q4 2025, 16.66% in Q3 2025, and 33.97% in Q2 2025.